Intercell kills diarrhea vaccine after study

	Tweet

Austrian biotech company Intercell said it won’t develop its Travelers’ Diarrhea vaccine candidate and will post a much wider than expected 2010 loss, because the drug failed in clinical trials.

The company said on Sunday that the patch-based Travelers’ Diarrhea vaccine candidate failed to meet efficacy endpoints to protect against enterotoxigenic E. coli mediated diarrheal infections in pivotal, randomized and placebo-controlled efficacy studies.

While it doesn’t plan to develop the vaccine anymore, Intercell said the studies support the continued investigation of its patch technology for future vaccines.

It expects its loss for 2010 to be “substantially higher” than its previous forecast of 40 million euros because it will not receive milestone payments in connection with the Travelers’ Diarrhea program.

The company said the intangible assets from the vaccine program had a book value of 167 million euros as of September

30. It plans to take a charge to write-down the value of all or a most of those assets that will also hurt the company’s 2010 results.

Intercell said it has decided to cut research and development spending by about 40 percent in 2011. It said the company will focus its resources on the other projects in its clinical stage portfolio.

###

(Reuters)

RELATED STORIES:
Leaked documents show Merck knew of Vioxx dangers, yet hid them for years   Parkinson’s drug may raise risk of valve trouble   Five VA patients blinded by Avastin injections: report   Celebrex risky in high-risk patients, study finds   Evidence supports ban on growth promotion use of antibiotics in farming   US urges doctors to report misleading drug pitches   Wide range of drugs abused by elite athletes   Japanese doctor adds insult and injury to patient   Internet tied to rise in drug abuse   BP drugs reduce pneumonia risk in stroke patients   Are silicofluorides controlled?   Cilexa safely curbs depression in the young

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]